品牌學名藥市場－全球產業規模、佔有率、趨勢、機會及預測，依藥品類別、應用、配銷通路、地區及競爭情況細分，2020-2030 年預測

2024 年全球品牌學名藥市場價值為 2,614.1 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 6.20%。品牌學名藥是指以不同的品牌名稱重新在市場上發布的藥品或藥物。這些產品以較低的成本重新發布，雖然藥物保持不變，但形狀、大小、顏色和味道可能會有所不同。這是因為該藥品或藥物的專利已經過期。為了留在市場上並在競爭中生存，用於治療高血壓、糖尿病、背痛、甲狀腺和關節炎等疾病的藥物以更低的價格重新上市。然而，必須強調的是，儘管在重新發布該藥物時做出了改變，但其品質仍然保持不變。藥物所發揮的功能不會受到任何損害。

主要市場促進因素

慢性病盛行率不斷上升

主要市場挑戰

監管障礙

主要市場趨勢

數位健康整合的進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第4章：顧客之聲

第5章：全球品牌學名藥市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類別（烷化劑、抗代謝物、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥、其他）
  • 依應用分類（腫瘤科、心血管疾病、神經系統疾病、急性及慢性疼痛、胃腸道疾病、皮膚病、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美品牌學名藥市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲品牌學名藥市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太品牌學名藥市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲品牌學名藥市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲品牌學名藥市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 合併與收購
• 產品發布

第 13 章：全球品牌學名藥市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sanofi-Aventis.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

Global Branded Generics Market was valued at USD 261.41 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.20% through 2030. Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a major driving force behind the expansion of the Global Branded Generics Market. Approximately 9 million people succumb to cancer annually, while 4 million deaths are attributed to chronic respiratory diseases like asthma and COPD, and another 2 million result from diabetes-related complications. However, the global distribution of disease burden and access to advanced healthcare solutions remains highly uneven, with disparities particularly evident in low- and middle-income regions where medical infrastructure, early diagnostics, and treatment accessibility are significantly limited. With a growing global disease burden, healthcare systems and consumers are increasingly turning to cost-effective and reliable treatment options, making branded generics a preferred choice. Chronic diseases such as cardiovascular diseases (CVDs), diabetes, cancer, respiratory disorders, and arthritis are becoming more prevalent due to factors such as aging populations, unhealthy lifestyles, and environmental changes. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for nearly 74% of all global deaths, highlighting the urgent need for long-term treatment solutions. Increased demand for continuous medication supply for long-term disease management. Greater emphasis on cost-effective treatment alternatives, making branded generics a viable solution. Higher healthcare spending by governments and private insurers to address chronic disease care.

Key Market Challenges

Regulatory Hurdles

Generic medications, including branded generics, need to go through regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.

Key Market Trends

Advancements in Digital Health Integration

Digital health technologies can improve patient engagement by providing tools for medication reminders, tracking, and adherence. Branded generics, as more affordable alternatives, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for chronic disease management. Digital health solutions enable remote monitoring of patients' health conditions, which is particularly useful for managing chronic diseases. This integration can enhance patient compliance with medication regimens, contributing to the growth of the market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics. Branded generics can be tailored to fit individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can improve awareness of branded generics among patients and healthcare providers. Through digital platforms, manufacturers can educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can use data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns. This information can guide marketing strategies and product positioning for branded generics.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sanofi-Aventis.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.

Report Scope:

In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Branded Generics Market, By Drug Class:

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti - Hypertensive
• Lipid Lowering Drugs
• Antidepressant
• Antipsychotics
• Antiepileptics
• Others

Branded Generics Market, By Application:

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Acute & Chronic Pain
• Gastrointestinal Diseases
• Dermatological Diseases
• Others

Branded Generics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Branded Generics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.

Available Customizations:

Global Branded Generics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Branded Generics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 5.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Branded Generics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 6.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Branded Generics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Branded Generics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Branded Generics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Branded Generics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Branded Generics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Branded Generics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Branded Generics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Branded Generics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Branded Generics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Branded Generics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Branded Generics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Branded Generics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Branded Generics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Branded Generics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Branded Generics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Branded Generics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Branded Generics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Branded Generics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Branded Generics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Branded Generics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Branded Generics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Branded Generics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Branded Generics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Branded Generics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Lupin Pharmaceuticals Inc.
• 15.3. Sanofi-Aventis.
• 15.4. Sun Pharmaceutical Industries Inc.
• 15.5. Dr Reddy's Laboratories Inc.
• 15.6. Endo International PLC.
• 15.7. GlaxoSmithKline LLC.
• 15.8. Pfizer Inc.
• 15.9. Viatris Inc.
• 15.10. Apotex Inc.

16. Strategic Recommendations

17. About Us & Disclaimer